Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies

Zusammenfassung

Cureus. 2025 Nov 13;17(11):e96739. doi: 10.7759/cureus.96739 Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies Syed S Raza Syed S Raza 1 Family Medicine, The Wright Center for Graduate Medical Education, Scranton, USA 2 Internal Medicine, Commonwealth Health Regional Hospital of Scranton, Scranton, USA Find articles by Syed S Raza 1,2, Zarshal Zakir Zarshal Zakir 3 Medicine, CHI St. Alexius Health, Bismarck, USA Fin

Kerninformationen

Approved long-term agents, orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide, semaglutide, and tirzepatide, differ in mechanism, weight-loss magnitude, and safety considerations. Semaglutide and tirzepatide have redefined expectations for pharmacological weight loss, while next-gen...

The first pathway reduces fat absorption (orlistat). The second pathway reduces appetite centrally (typically seen with phentermine/topiramate and naltrexone/bupropion). The third pathway uses incretin biology to reduce appetite, slow gastric emptying, and improve metabolic control (liraglutide, sem...

We structured our work around the Scale for the Assessment of Narrative Review Articles criteria to keep the process clear, rigorous, and relevant [12]. Search Strategy We searched PubMed, MEDLINE, EMBASE, Google Scholar, Scopus, and the Cochrane Library for studies published from 1990 to 2025. We c...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen